Crossmark

Protection from neurodegeneration in the 6-hydroxydopamine (6-OHDA) model of Parkinson's with novel 1-hydroxypyridin-2-one metal chelators

Crossref DOI link: https://doi.org/10.1039/C4MT00326H

Published Online: 2015

Update policy: https://doi.org/10.1039/rsc_crossmark_policy

Authors

Workman, David G.

Tsatsanis, Andrew

Lewis, Frank W.

Boyle, John P.

Mousadoust, Maryam

Hettiarachchi, Nishani T.

Hunter, Michael

Peers, Chris S.

Tétard, David

Duce, James A.
Funding

Funding for this research was provided by:

European Research Council

Healthcare Infection Society

Parkinson's UK

Alzheimer's Research Trust
More Information

CROSSCHECK

: This document is CrossCheck deposited

RELATED DATA

: Supplementary Information

: Crystal Structure Data

COPYRIGHT AND LICENSING

: The Royal Society of Chemistry has an exclusive publication licence for this journal

OPEN ACCESS: This article is freely available. This article is licensed under a Creative Commons Attribution 3.0 Unported Licence (CC BY 3.0)

PUBLICATION HISTORY

: Received 9 December 2014; Accepted 9 March 2015; Accepted Manuscript published 10 March 2015; Advance Article published 17 March 2015; Version of Record published 13 May 2015